Pall the ‘stand-out’ in Danaher’s life sciences Q4 results

By Staff Reporter

- Last updated on GMT


Related tags Revenue Puerto rico

Pall Corporation reported its best quarterly growth since its acquisition by Danaher in 2015.

Danaher reported a solid fourth quarter yesterday, with its life sciences business clocking in sales of $1.6bn, up 12% on the same period 2016.

This included a core revenue growth of nearly 10% with its Pall division, making the 2015 acquisition​ the “stand-out”​ within the life sciences business, Jefferies analyst Brandon Couillard wrote in a note.

When Danaher closed the $14bn acquisition in September 2015, it entered the bioprocessing space through Pall’s filtration, separation and purification technologies.

According to Danaher CEO Tom Joyce, this represented Pall’s best quarterly growth rate since the acquisition, and was down to the continued performance of microelectronics and single-use technologies.

He also told stakeholders Pall had recovered from recent setbacks leaving biopharma to finish the year on a strong note, having “rebounded nicely from the hurricane disruptions [in Florida and Puerto Rico] that impacted third quarter results.”

He added: “We saw good order rate trends around biologic and small molecules, good order rate trend around our single use technologies as well. So on balance I would say, the overall pharma market, biologics and small molecules combined continues to be in pretty good shape.”

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more